A single centric, prospective, open label, interventional study to evaluate the efficacy and safety of CitriobioShield as an adjunct with standard of care therapy in improving immunity in mild to moderate COVID 19 patients through inhalation of fog.

GERMKILL INDIA0 个研究点目标入组 20 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male or non-pregnant female between 18 to 65 years of age at the time of enrolment.
•2.Subject or LAR providing written informed consent and agrees to follow study procedure.
•3.Woman with child bearing potential confirming use of primary contraception
•4.Mild to moderate freshly confirmed COVID 19 positive subjects in less than 24 hours not requiring emergency or ICU care at the time of enrolment

•1.Severe COVID 19 patients requiring ventilation or oxygen support when diagnosed.
•2.Females who are planning to conceive during the study duration or are pregnant already or are breastfeeding.
•3.Subjects having serious or unstable respiratory disorders (self-reported)
•4.Subject already on immune therapy (self-reported)
•5.Immunodeficiency or organ transplant (self-reported)
•6.Autoimmune disease (self-reported)
•7.Current acute infection or exacerbation of a chronic illness (self-reported)
•8.Cancer within last 5 years (self-reported)
•9.Known infection with HIV, Hepatitis B & Hepatitis C (self-reported)
•10.Drug abuse/alcohol abuse (self-reported)
•11.Plasma donation within last 4 months (self-reported)
•12.Receiving blood or immunoglobulins within 3 months (self-reported)
•13.SGOT/SGPT greater than 5 times normal value (self-reported)

发起方

GERMKILL INDIA